WuXi Biologics’ pre-filled syringes (PFS) commercial production line passed its first FDA inspection, paving the way for global delivery of high-quality PFS solutions to clients worldwide Reinforces WuXi Biologics’ strong track record of a 100% success […]
Tag: WuXi Biologics
WuXi Biologics Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL
The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrations up to 230 mg/mL It reduces viscosity by up to 90% while maintaining formulation stability and injectability SHANGHAI, June 30, 2025 /PRNewswire/ […]
WuXi Biologics Ireland Receives 2025 Operational Excellence in Life Sciences Award
DUNDALK, Ireland, June 16, 2025 /PRNewswire/ — WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that its Ireland site has been honored with the prestigious 2025 Operational Excellence in […]
WuXi Biologics Kicks off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu
The microbial manufacturing site in Chengdu will be equipped with a 15,000L fermenter, enabling the production of 80 to 110 drug substance (DS) batches annually with expansion potential to 60,000L. It will house China’s first […]
WuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for Gaucher Disease by China NMPA
Enabled by WuXi Biologics’ industry-leading integrated technology platform, velaglucerase-beta for injection has successfully advanced from concept to commercialization. Velaglucerase-beta for injection, as the first and the only locally developed enzyme replacement therapy (ERT) for Gaucher […]
